William Ben Jones

William Ben Jones is the Senior Vice President of Pharmaceutical Development at Corvus Pharmaceuticals. William has over 17 years of experience in the pharmaceutical industry, with a focus on oncology.

Jones began their career at Vertex Pharmaceuticals in February 2002 as a Sr. Program Manager in Strategic Development. William then moved to Plexxikon Inc. in August 2005 as an Associate Director of Development. In January 2008, they joined Pharmacyclics as the Director of Regulatory Affairs and Project Management.

In December 2012, Jones joined Sanofi as the Director of Global Regulatory Affairs. In this role, they led the global regulatory affairs team for multiple small molecules and biologics for oncology, including the post marketing team for Leukine (GM-CSF) and early development of isatuximab (Sarclisa), an intravenously administered, CD38-directed cytolytic monoclonal antibody for the treatment of multiple myeloma.

Jones has been with Corvus Pharmaceuticals since December 2014 and currently serves as the Senior Vice President of Pharmaceutical Development.

William Ben Jones started their educational career by completing a Bachelor of Science in Chemistry from the University of Cincinnati. William then went on to complete a Doctor of Philosophy in Chemistry from the same school. After that, they completed a Post Doctoral Fellowship in Chemistry at the University of Oxford. Finally, they completed a Master of Business Administration from the Babson F.W. Olin Graduate School of Business.

William Ben Jones reports to Richard A. Miller, M.D., Co-Founder, CEO & President. Some of their coworkers include Long Kwei - SVP, Biometrics, James W. Janc - Vice President, Pharmacology, and Leiv Lea - Chief Financial Officer.